This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Legal Questions Still Dogging Wyeth

"In 2007 alone, Wyeth experienced setbacks with Pristiq, Viviant, Aprela and bifeprunox that reduced or erased the commercial prospects of these assets," Schott explains. The FDA rejected bifeprunox for schizophrenia in August 2007.

In July 2007, the FDA granted conditional approval for Pristiq, a non-hormonal treatment for menopausal symptoms. To gain final approval, Wyeth must conduct a clinical trial to assess potential heart and liver side effects. The trial is expected to take 18 months. In February 2008, the FDA approved Pristiq as a treatment for depression in adults.

In May, the FDA granted conditional approval for Viviant to treat postmenopausal osteoporosis. In December 2007, the FDA gave tentative clearance for Viviant to prevent the disease. Final approval for both uses depends on Wyeth's answering the FDA's questions about risks of stroke and blood clots in leg veins, expected by year-end. Schott figures the FDA will act by mid-2009.

Viviant could come to market in 2010, but Schott says Aprela has greater revenue potential. Aprela, which is still in late-stage clinical trials, combines Premarin and Viviant. Clearly, if the FDA rejects or restricts Viviant, potential sales of Aprela will be affected. Wyeth expects to seek FDA approval for Aprela in the middle of next year.

5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
MRK $57.75 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%
GOOG $548.34 0.00%
TSLA $185.00 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs